ClinicalTrials.gov
ClinicalTrials.gov Menu

Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03457818
Recruitment Status : Not yet recruiting
First Posted : March 8, 2018
Last Update Posted : March 8, 2018
Sponsor:
Information provided by (Responsible Party):
Mishaela Rubin, Columbia University

Brief Summary:
The goal of the study is to characterize the effect of Prolia® (denosumab, AMG 162; Human Monoclonal Antibody to RANK, Ligand) on indices of bone strength in type 2 diabetes (T2D). The investigational plan involves administration of Prolia® or identical placebo for 12 months as a randomized double-blind placebo-controlled trial in 66 T2D postmenopausal women assigned to Prolia® or placebo. The study will include assessment of different measures of bone quality: skeletal microarchitecture, including measurement of skeletal cortical pores; bone mineral density; bone material quality, and accumulation of advanced glycation endproducts (AGEs) in collagen. This information will help to determine whether Prolia® treatment in type 2 diabetes has skeletal benefits.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 2 Osteoporosis Drug: Denosumab 60 MG/ML Other: Placebo Phase 2

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 66 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study is a 12 month randomized (2:1 assignment) double-blind placebo-controlled trial of T2D postmenopausal women assigned to either DMAb 60 mg SC at baseline and 6 months (n=44) or placebo (n=22); total study n=66.
Masking: Double (Participant, Investigator)
Masking Description: Clinical Research Coordinators
Primary Purpose: Prevention
Official Title: Therapy of the Skeletal Disease of Type 2 Diabetes With Denosumab
Estimated Study Start Date : June 1, 2018
Estimated Primary Completion Date : April 1, 2021
Estimated Study Completion Date : July 1, 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Denosumab
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Treatment Group
Denosumab 60 mg/mL SC at baseline and 6 months.
Drug: Denosumab 60 MG/ML
Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
Other Name: Prolia®
Placebo Comparator: Control Group
Placebo SC at Baseline and 6 months.
Other: Placebo
Placebo will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits



Primary Outcome Measures :
  1. Change in cortical porosity (%) by HRpQCT imaging from baseline to 6 and 12 months. [ Time Frame: Baseline, 6 months and 12 months ]
    The primary outcome is the 12 months change in Ct.Po and the primary intent-to-treat analysis is a one-way ANCOVA with the fixed effect of treatment (treated vs. placebo), and baseline Ct.Po as a continuous covariate.


Secondary Outcome Measures :
  1. Change in s-CTX (ng/ml) and TRAP-5b (ng/ml) by blood test from baseline to 3, 6 and 12 months. [ Time Frame: Baseline, 3 months, 6 months and 12 months ]
    Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.

  2. Change in DXA (gm/cm2) at lumbar spine, femoral neck, total hip and radius from baseline to 6 and 12 months. [ Time Frame: Screening visit, 6 months and 12 months ]
    Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.

  3. Change in BMSi (unitless) by IMI from baseline to 12 months. [ Time Frame: Baseline and 12 months ]
    Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.

  4. Change in SAF (unitless) from baseline to 6 and 12 months. [ Time Frame: Baseline, 6 months and 12 months ]
    Secondary outcomes will be analyzed using ANCOVA models with P-value adjustment for multiple endpoint comparisons.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. An understanding, ability and willingness to fully comply with study procedures and restrictions.
  2. Ability to voluntarily provide written, signed and dated informed consent as applicable to participate in the study.
  3. Postmenopausal women age ≥ 55 and ≤ 75 years at time of consent.
  4. Diagnosis of T2D for ≥ 10 years. Upon review of patient's medical history, patient will be confirmed to currently have reasonably controlled T2D as assessed by the investigator, with HbA1c ≤ 8.4%. If HbA1c is ≥ 8.5%, re-screening will be allowed after approximately 3 months following adjustment of diabetes therapy.
  5. Dual energy x-ray absorptiometry (DXA) T-score ≤ -1.5 at one or more sites (lumbar spine, femoral neck, total hip or distal 1/3 radius).
  6. Normal albumin-adjusted serum calcium level.

Exclusion Criteria:

  1. Hormone replacement treatment use (to avoid the influence of estrogen).
  2. Fractures (excluding skull, facial bones, metacarpals, fingers, toes, and fractures associated with severe trauma) within 12 months.
  3. A history of pathological fractures (eg, due to Paget's disease, myeloma, metastatic malignancy).
  4. Type 1 diabetes.
  5. Disorders associated with altered skeletal structure or function (chronic renal disease stage 4 or worse, chronic liver disease, malignancy, hypoparathyroidism or hyperparathyroidism, acromegaly, Cushing's syndrome, hypopituitarism, chronic obstructive pulmonary disease, alcohol intake > 3U/day).
  6. Treatment for blood clots or coagulopathy.
  7. Treatment with any of the following drugs in past year: corticosteroids ≥ 5 mg/day (>3 mos. at any time or >10 days), anticonvulsant therapy, pharmacological doses of thyroid hormone (TSH<normal), adrenal or anabolic steroids, aromatase inhibitors, calcitonin, bisphosphonates, estrogen or selective estrogen receptor modulator, sodium fluoride, teriparatide, thiazolidinediones (TZDs), SGLT2 inhibitors.
  8. Serum 25(OH)D levels < 20 ng/ml. If 25(OH)D levels are < 20 ng/ml, rescreening will be allowed following a vitamin D loading regimen of 50,000 IU/week for 4 weeks. If serum 25(OH)D levels are ≥ 20 ng/ml after supplementation, the subject will be allowed to enroll.
  9. Clinically significant hypersensitivity to denosumab or any components of denosumab 60 mg.
  10. Known sensitivity to any of the products to be administered during the study (e.g., calcium or vitamin D).
  11. Subject is pregnant or breast feeding, or planning to become pregnant within 5 months after the end of treatment.
  12. Female subject of child bearing potential and is not willing to use, in combination with her partner, highly effective contraception during treatment and for 5 months after the end of treatment.
  13. Significant dental/oral disease, including prior history or current evidence of osteonecrosis/osteomyelitis of the jaw, or the following:

    • Active dental or jaw condition which requires oral surgery
    • Non-healed dental/oral surgery
    • Planned invasive dental procedures for the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03457818


Contacts
Contact: Maximo Gomez, M.D 212-304-5536 meg2230@columbia.edu
Contact: Rukshana Majeed, B.A 212-305-9489 rm3324@columbia.edu

Locations
United States, New York
Columbia University Medical Center - Harkness Pavillion Not yet recruiting
New York, New York, United States, 10032
Contact: Rukshana Majeed Clinical Research Coordinator    212-305-9489    rm3324@columbia.edu   
Contact: Beatriz Omeragic Clinical Research Coordinator    212-305-7364    bo2248@columbia.edu   
Principal Investigator: Mishaela Rubin, M.D.         
Sub-Investigator: Jessica Starr, M.D.         
Sponsors and Collaborators
Mishaela Rubin
Investigators
Principal Investigator: Mishaela Rubin, M.D Columbia University

Publications of Results:
Other Publications:
Responsible Party: Mishaela Rubin, Associate Professor of Medicine, Columbia University
ClinicalTrials.gov Identifier: NCT03457818     History of Changes
Other Study ID Numbers: Prolia ISS #20177161
First Posted: March 8, 2018    Key Record Dates
Last Update Posted: March 8, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Diabetes Mellitus
Osteoporosis
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Denosumab
Bone Density Conservation Agents
Physiological Effects of Drugs